The genesis and evolution of high-grade serous ovarian cancer

@article{Bowtell2010TheGA,
  title={The genesis and evolution of high-grade serous ovarian cancer},
  author={David D. L. Bowtell},
  journal={Nature Reviews Cancer},
  year={2010},
  volume={10},
  pages={803-808}
}
  • D. Bowtell
  • Published 1 November 2010
  • Biology, Medicine
  • Nature Reviews Cancer
Germline mutation in either BRCA1 or BRCA2 is associated with an increased risk of ovarian cancer, particularly the most common invasive histotype — serous carcinoma. In addition, serous ovarian cancers have an unusually high frequency of other molecular events involving BRCA pathway dysfunction. Recent findings show a high frequency of TP53 mutation, chromosomal instability, distinct molecular subtypes and DNA copy number-driven changes in gene expression. These findings suggest a model in… 
The changing view of high-grade serous ovarian cancer.
TLDR
The classification of epithelial ovarian cancer has been substantially revised, with an increased appreciation of the cellular origins and molecular aberrations of the different histotypes and novel molecular subtypes associated with distinct biology and clinical outcome.
The mutational profile of sporadic epithelial ovarian carcinoma.
TLDR
It is expected that mutation profiling will become integrated into current morphological/immunohistochemical primary diagnostic assessment of tumours once the cost and quality control issues of the technology are addressed.
Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies
TLDR
High-grade serous ovarian carcinoma accounts for the majority of the ovarian cancer deaths, but over the last years little improvement in overall survival has been achieved, and molecular stratification of HGSOC based on genomic features may result in improved therapeutic strategies.
Most commonly mutated genes in High Grade Serous Ovarian Carcinoma are nonessential for ovarian surface epithelial stem cell transformation
TLDR
A model in which combined disruption of RB1 and PTEN, in addition to TP53 deficiency, constitutes a core set of mutations required for efficient transformation in vitro is suggested, which support the OSE stem cell theory of HGSOC initiation and suggest that most commonly mutated genes in H GSOC have no effect on OSE-SC transformation initiation.
Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation.
TLDR
The results indicate that disruption of TP53 and PTEN, combined with RB1 disruption, constitutes a core set of mutations driving efficient transformation in vitro and suggest that most commonly mutated genes in HGSOC have no effect on OSE-SC transformation initiation.
Synthetic lethality between CCNE1 amplification and loss of BRCA1
TLDR
It is shown that BRCA1 and members of the ubiquitin pathway are selectively required in cancers that harbor CC NE1 amplification, and specific sensitivity of CCNE1-amplified tumor cells to the proteasome inhibitor bortezomib is shown.
Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
  • I. Otsuka
  • Medicine
    International journal of molecular sciences
  • 2021
TLDR
Current carcinogenic hypotheses, sites of origin, etiologic factors, and molecular alterations of HGSCs are discussed, and HR deficiency and the CCNE1 amplification appear to be mutually exclusive.
Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
TLDR
A novel subtype of patients with HGSOC is demonstrated by an intact p53 pathway, with limited genomic alterations and specific gene expression profiles, which indicates the involvement of specific biological processes that are relevant to genomic stability and cancer etiology.
Clonal evolution of high‐grade serous ovarian carcinoma from primary to recurrent disease
TLDR
These findings provide the first evidence at single nucleotide resolution that recurrent HGSC arises from multiple clones present in the primary tumour with negligible accumulation of new mutations during standard treatment.
Targeting the epigenome in ovarian cancer.
TLDR
Epigenetic therapies are emerging as promising agents for resensitizing platinum-resistant ovarian cancers and may also have the potential to alter epigenetic programming in cancer progenitor cells and provide a strategy for improving therapy of ovarian cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
TLDR
It is concluded that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers because it is almost invariably present in HGPSCs, and is not of substantial prognostic or predictive significance.
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
TLDR
Overexpression of p53 with loss of p21 expression occurred significantly more frequently in high grade serous carcinomas with epigenetic loss of BRCA1, compared to highgrade serous tumors without loss of PIK3CA.
Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems
TLDR
An update is provided on the pathogenesis and clinicopathologic features of these 2 types of serous carcinomas and addresses some of the diagnostic problems that are encountered in routine practice.
Large‐scale genomic analysis of ovarian carcinomas
TLDR
High‐resolution array technologies have provided the first glimpse of the remarkable complexity of genomic aberrations with some ovarian cancers containing hundreds of copy number breakpoints, micro‐deletions and amplifications, suggesting that the majority of changes contain cancer‐related genes.
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
TLDR
The p53 signature and its malignant counterpart (TIC) underline the significance of the fimbria, both as a candidate site for serous carcinogenesis and as a target for future research on the early detection and prevention of this disease.
Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer
TLDR
A model for pelvic serous cancer is proposed that takes into account five distinct variables which ultimately impact on origin and tumor distribution; these entities are useful as both surrogate endpoints for their respective malignancies in epidemiologic studies and natural targets for cancer prevention.
Hallmarks of 'BRCAness' in sporadic cancers
TLDR
There are properties that define 'BRCAness' — that is, traits that some sporadic cancers share with those occurring in either BRCA1- or BRCa2-mutation carriers, which might have important implications for the clinical management of these cancers.
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.
TLDR
The tubal p53 signature merits serious consideration as an important early event in serous carcinogenesis in BRCA+ women.
Frequency of BRCA1 dysfunction in ovarian cancer.
TLDR
The use of LOH, rather than a family history of ovarian cancer, as a first step in a screening strategy, followed by protein truncation testing, appears to increase the chance of identifying tumors with BRCA1 dysfunction.
The molecular pathogenesis of hereditary ovarian carcinoma
TLDR
The authors of this report investigated alterations in BRCA1/2 tubal epithelium to define the molecular pathogenesis of these carcinomas.
...
1
2
3
4
5
...